API Market Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

API Market Challenges
Boris Jenniches, Head of Global marketing APIs and Standard Excipients at BASF SE, tells Pharmaceutical Technology Europe about the impact of the financial crisis on the API market.


Pharmaceutical Technology Europe
Volume 23, Issue 9

What common API problems continue to plague pharmaceutical manufacturers?

The solubility and, hence, bioavailability of APIs — particularly new APIs — is an increasing industry problem for many reasons including:

  • High-throughput screening is resulting in more complex API structures with an increase in BCS Class II (low solubility and high permeability) and Class IV (low solubility and low permeability).
  • A large number of recent drug candidates or new APIs are in Class II.
  • About 40% of the APIs currently on the market show poor solubility and 90% of the APIs in development are poorly soluble!
  • Numerous APIs do not even enter development due to extremely low solubility in water.

In many cases, the formulation has to bring a high dosage of the drug to increase its bioavailability, which can lead to unreliable efficacy, an increase in costs and stability problems.

For many years, the industry has conducted research and development into new excipients in order to help overcome the above issues. Today, a wide range of solubilisers and solvents are available. One technology that has gained significant interest is hot melt extrusion (HME). Although this technique has been used in the plastics and food industries for decades, it is relatively new in the pharmaceutical industry and only a few drug products are currently available on the market. The technology shows numerous benefits over traditional/classical methods including shorter processing times because of continuous downstream processes, environmental advantages due to elimination of solvents, and increased efficiency in drug delivery.

Looking ahead five years for now, how do you see the market for APIs evolving?

The market for APIs continues to grow above the overall pharma market because of the trend towards generics in both the established and emerging markets. For pharma companies, we will see ongoing consolidation and a stronger focus on the emerging markets, which are experiencing high-growth rates because of their increased expenditure on healthcare.

Suppliers and pharma companies will have to address the specific needs of the consumers in this regions with specially tailored products and new solutions that serve these markets in a cost-competitive way. To meet this challenges, it can be beneficial for companies to partner with global suppliers that help them to both reduce costs and cope with the unique challenges posed by emerging markets, such as local regulatory requirements and the fluctuations that are often seen in demand. Indeed, because of the rising complexity of business in the pharma landscape, selecting the right API supplier is becoming ever-more important.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here